Metabolize
Developing non-drug metabolic-health products from Stanford Medicine-originated research, starting with NATLEAN for GLP-1 users.
Website: https://metabolize.life/
Cover Block
Publicly reported
| Field | Detail |
|---|---|
| Name | Metabolize |
| Tagline | Developing non-drug metabolic-health products from Stanford Medicine-originated research, starting with NATLEAN for GLP-1 users [EconoTimes, October 2026] [PR Newswire, July 2024] |
| Headquarters | San Francisco, USA [EconoTimes, October 2026] |
| Founded | 2024 [PR Newswire, July 2024] |
| Stage | Seed [FinSMEs, October 2026] |
| Business model | Direct-to-consumer [metabolize.life] |
| Industry | Healthtech [EconoTimes, October 2026] |
| Technology | Biotech / Life Sciences [PR Newswire, July 2024] |
| Geography | North America [EconoTimes, October 2026] |
| Growth profile | Venture scale [FinSMEs, October 2026] |
| Founding team | Co-Founders (2): Morris Laster and Gideon Meir [PR Newswire, July 2024] [LinkedIn, Retrieved 2026] |
| Funding label | Seed |
| Total disclosed | $3.2 million [EconoTimes, October 2026] [Citybiz, October 2026] |
Links
Publicly reported
- Website: https://metabolize.life/
Summary and Signal
PUBLIC Metabolize is a San Francisco consumer health startup building non-drug metabolic health products from Stanford-originated research, and it merits investor attention now because it has moved from licensing science into a financed pre-launch commercialization window around GLP-1 user retention and step-down support [PR Newswire, July 2024] [EconoTimes, October 2026] [Citybiz, October 2026]. The company was founded in 2024, though Morris Laster has described the effort as beginning in 2022, which suggests a research-to-company formation arc rather than a purely opportunistic product spin-up [PR Newswire, July 2024] [NoCamels, October 2024]. Its lead product, NATLEAN, is positioned as a daily supplement for people transitioning off GLP-1 therapies, with the company tying the formulation to an exclusive Stanford license and to published metabolite research rather than to a prescription pathway [Citybiz, October 2026] [PR Newswire, July 2024] [metabolize.life].
The commercial differentiation, if it holds up, is not novel software or a new drug application, but a narrower bet that a licensed metabolite-based nutraceutical can address appetite regulation and weight maintenance with faster time to market than a pharmaceutical program [NoCamels, October 2024] [PR Newswire, July 2024]. Leadership is anchored by co-founder and CEO Morris Laster, whose public profile includes senior investing roles at OurCrowd, while co-founder Gideon Meir is identified by the company as COO and previously a senior executive at Standard Industries; the underlying academic research is associated with Stanford pathologist Jonathan Long, who is not presented in the cited public sources as a founder [Bloomberg] [TechCrunch, September 2022] [PR Newswire, July 2024] [LinkedIn, Retrieved 2026]. Metabolize operates a direct-to-consumer model and announced $3.2 million in seed financing in October 2026, led by Astanor with participation from Maia Ventures, LongGame Venture, and SOSV, after earlier SOSV-backed seed reporting in 2025 [EconoTimes, October 2026] [FinSMEs, October 2026].
The next 12 to 18 months turn on execution rather than category education: whether NATLEAN launches on the stated January 2027 timeline, whether the company can substantiate efficacy claims within supplement marketing constraints, and whether paid consumer demand emerges beyond the current science-forward narrative [Citybiz, October 2026] [metabolize.life]. Public evidence remains strongest on the financing, Stanford licensing, and team identities, and materially weaker on product performance, customer traction, and the durability of the DTC thesis in a crowded weight-management market [PR Newswire, July 2024] [EconoTimes, October 2026] [metabolize.life].
One source, partially checked -- Core company formation, financing, and licensing claims are corroborated by PR Newswire, EconoTimes, Citybiz, FinSMEs, Bloomberg, and LinkedIn, while product efficacy and launch-positioning details rely materially on company-linked sources.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed approximately $3.2 million [EconoTimes, October 2026] |
Company Overview
Publicly reported Metabolize presents as a young consumer health company built around a narrow, specific bet: that licensed metabolite science can support weight maintenance without a prescription. The company was founded in 2024 and is based in San Francisco, according to its website and public company summary materials [metabolize.life] [PR Newswire, July 2024]. Its public positioning centers on non-drug metabolic-health products originating from Stanford research, with NATLEAN named as the first commercial product on the site [metabolize.life].
The chronology that can be established from company-linked public sources is limited but coherent. In July 2024, Metabolize announced that it had licensed two proprietary metabolites from Stanford's Office of Technology Licensing for development as nutraceuticals, a milestone that appears to mark the company's first clear public step into commercialization [PR Newswire, July 2024]. By the time of its current website, the company was publicly marketing NATLEAN directly to consumers and describing it as a daily supplement for appetite and weight-maintenance support, with claims framed under standard dietary supplement disclosures [metabolize.life].
The founding team publicly identified in company-adjacent materials consists of Morris Laster as founder and CEO and Gideon Meir as COO, with the broader scientific origin story tied to research from Stanford Medicine [PR Newswire, July 2024] [metabolize.life]. Public materials do not add much on legal entity structure or incorporation details, so the cleaner read is that this remains an early-stage San Francisco startup with a Stanford-linked licensing foundation and an emerging direct-to-consumer launch motion rather than a fully documented operating history [metabolize.life] [PR Newswire, July 2024].
One source, partially checked -- Confirmed primarily by the company website and company announcement, with partial corroboration across public company-linked sources.
The Product and the Stack
MIXED
The product story is relatively straightforward, and the interesting part is where the company draws the line. Metabolize is developing non-drug metabolic-health products from Stanford-originated research, with NATLEAN as its first announced consumer offering for people transitioning off GLP-1 therapies [PR Newswire, July 2024] [EconoTimes, October 2026] [Citybiz, October 2026]. On its website, the company presents NATLEAN as a supplement for appetite and weight-maintenance support, states that no prescription is required, and prices the product at $69 per month [PUBLIC] [metabolize.life].
The underlying mechanism is described in public materials, but mostly through company framing rather than independent technical validation. The website says NATLEAN is a daily supplement combining N-acetyltaurine and taurine, and that it is intended to help quiet "food noise," support healthy appetite regulation, weight maintenance, and lean muscle support [PUBLIC] [metabolize.life]. Separately, the company announced in July 2024 that it had licensed two proprietary metabolites from Stanford's Office of Technology Licensing for development as nutraceuticals, and later coverage tied that platform to NATLEAN's positioning for post-GLP-1 users [PUBLIC] [PR Newswire, July 2024] [Citybiz, October 2026]. The site also includes the standard supplement disclaimer that the statements have not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent any disease [PUBLIC] [metabolize.life].
What can be said with confidence is narrower than the marketing language. Public evidence supports that Metabolize is commercializing a consumer supplement, not a prescription therapeutic, and that the product thesis rests on licensed Stanford-related metabolite research rather than a disclosed software or device stack [PR Newswire, July 2024] [metabolize.life]. Public reporting also indicates a planned January 2027 launch for NATLEAN, although the efficacy claims around appetite regulation and weight maintenance should be read as company claims unless and until independent clinical data are disclosed [Citybiz, October 2026] [EconoTimes, October 2026].
No independent source found -- Core product details are confirmed by the company website and company-linked announcements, with partial corroboration from Citybiz and EconoTimes, but the material efficacy and mechanism claims remain primarily company-sourced.
The Market They Are Entering
PUBLIC
The market matters now because GLP-1 adoption has expanded the weight-management funnel, but persistence, affordability, and post-treatment maintenance remain unsettled pieces of the consumer-health stack [Citybiz, October 2026] [EconoTimes, October 2026].
Metabolize is positioning into that gap rather than into the prescription market itself. Public source material does not provide a third-party TAM, SAM, or SOM for metabolite-based supplements for people transitioning off GLP-1 therapies, so the cleanest framing is through adjacent markets. The company and press coverage repeatedly describe NATLEAN as a non-prescription supplement aimed at appetite regulation and weight maintenance for people coming off GLP-1 drugs, which places it at the intersection of consumer weight management, nutraceuticals, and GLP-1-adjacent support products [metabolize.life] [Citybiz, October 2026] [PR Newswire, July 2024]. That is a commercially interesting wedge if demand proves durable, because it avoids the longer path associated with prescription therapeutics while still tying itself to one of the largest current health categories in consumer attention [NoCamels, October 2024] [PR Newswire, July 2024].
Demand drivers are visible even in the limited public record. The company has anchored its pitch to users who want help maintaining weight loss or managing appetite after GLP-1 use, and its homepage speaks directly to persistent hunger and "food noise," language that has become familiar to weight-loss consumers rather than to clinicians alone [metabolize.life] [Citybiz, October 2026]. The public materials also stress a no-prescription format and monthly pricing visible on the site, which suggests management believes accessibility and out-of-pocket affordability are part of the purchase case, not just efficacy claims [metabolize.life].
Substitute markets are broad, which cuts both ways. On one side, Metabolize can draw from adjacent spend already flowing to OTC appetite support, weight-maintenance supplements, functional wellness products, and broader DTC metabolic-health offerings [metabolize.life] [NoCamels, October 2024]. On the other, those same categories are crowded and often weakly differentiated, so any real market capture will likely depend less on category expansion than on whether Stanford-linked science and GLP-1-specific positioning create enough trust to justify sustained consumer adoption [PR Newswire, July 2024] [NoCamels, October 2024].
Regulatory and macro conditions are central here because they shape both speed and limits. The company has said it is commercializing licensed metabolites as nutraceuticals and its website includes the standard supplement disclaimer that the product is not intended to diagnose, treat, cure, or prevent disease [PR Newswire, July 2024] [metabolize.life]. That likely shortens the route to market relative to a drug program, but it also means the company will operate in a category where consumer marketing, substantiation standards, and claim discipline matter as much as laboratory novelty [NoCamels, October 2024] [metabolize.life].
| Market lens | Public evidence | Relevance to Metabolize |
|---|---|---|
| GLP-1 transition support | NATLEAN is described as intended for people transitioning off GLP-1 therapies [Citybiz, October 2026] [EconoTimes, October 2026] | Defines the initial demand wedge rather than a general wellness audience |
| Nutraceuticals / supplements | Metabolize licensed metabolites for development as nutraceuticals; NATLEAN is sold as a supplement with FDA disclaimer language [PR Newswire, July 2024] [metabolize.life] | Suggests a faster commercialization path, with lower regulatory burden than prescription drugs |
| Weight maintenance / appetite support | Website language centers on appetite regulation, food-noise reduction, and weight maintenance [metabolize.life] | Indicates the company is targeting repeat-use consumer behavior, not one-time treatment episodes |
| Science-backed consumer health | The company ties product credibility to Stanford licensing and research cited on-site [PR Newswire, July 2024] [metabolize.life] | If validated in market, scientific provenance could support premium positioning in a crowded OTC field |
The public evidence points to a real, timely buying context, but not yet to a measured market size specific to Metabolize's niche. For now, the investable question is less the category's existence than whether GLP-1 off-ramp demand is large and recurring enough for a supplement brand to build efficient customer acquisition around it.
No independent source found -- This section relies mainly on company materials and press reprints for positioning and market framing, with no independent third-party market-sizing report cited.
The Competitive Field
The Competitive Field
MIXED Metabolize is not competing head-on with GLP-1 drug makers so much as trying to sell into the drop-off point those drugs leave behind, with a non-prescription product aimed at appetite regulation and weight maintenance after therapy [PR Newswire, July 2024] [EconoTimes, October 2026] [metabolize.life].
The competitive map is defined less by named startup peers in the sourced record and more by three public alternative sets. The first is incumbent prescription therapy, particularly GLP-1 drugs, which set the reference standard for weight-loss efficacy but also create the user transition that NATLEAN is built around [EconoTimes, October 2026] [Citybiz, October 2026]. The second is the broad supplement market for appetite, weight management, and metabolic health, where products can launch faster and sell direct to consumers but often struggle to distinguish science from branding [PR Newswire, July 2024] [metabolize.life]. The third is adjacent consumer health programs, including behavior-change and maintenance offerings that do not rely on a proprietary ingredient at all. On the public record, Metabolize sits between pharma efficacy and supplement accessibility, which is an interesting slot, but also one that is crowded by category rather than by any single named rival in the materials provided.
The clearest edge visible today is sourcing and scientific origin. Metabolize has publicly said it secured an exclusive Stanford license covering two proprietary metabolites, and its messaging consistently ties NATLEAN to research associated with Stanford scientist Jonathan Long [PR Newswire, July 2024] [NoCamels, October 2024] [metabolize.life]. That matters because consumer metabolic-health products usually compete on formulation, influencer distribution, or price, while Metabolize is trying to compete on translational science and licensed IP. The difficulty is that this edge may be durable in narrative and ingredient access, but perishable in market impact unless it is matched by credible human data, repeat purchase behavior, and disciplined DTC acquisition economics, none of which are established in the public record [EconoTimes, October 2026] [Citybiz, October 2026].
The company is most exposed where it does not control the reference outcome. Novo Nordisk and Eli Lilly are not named in the source set, so it would be a step too far to map Metabolize directly against either company here, but the category exposure is plain: if prescription GLP-1 users stay on therapy longer, taper more slowly under physician supervision, or shift to maintenance regimens within the healthcare system, the standalone consumer handoff point narrows. Metabolize is also exposed to generic supplement competition because no owned clinical channel, payer channel, or large-scale provider distribution relationship appears in the cited material [PR Newswire, July 2024] [IndieBio / LinkedIn, January 2026]. A Stanford-backed license can help establish credibility, but it does not by itself secure shelf space, search efficiency, or physician endorsement.
The most plausible 18-month scenario is a polarized one. The winner if X is Metabolize, if the January 2027 NATLEAN launch converts Stanford-linked scientific credibility into a repeatable DTC wedge among users coming off GLP-1 therapies, especially if early retention shows the product is solving a real maintenance problem rather than attracting one-time curiosity buyers [Citybiz, October 2026] [metabolize.life]. The loser if Y is the undifferentiated supplement cohort, if consumers begin to prefer products with identifiable licensed science over broad weight-management claims. The inverse also holds: Metabolize is the likely loser if post-GLP-1 demand proves narrower than management expects, or if consumers treat NATLEAN as interchangeable with lower-cost appetite-support supplements once it is in market [EconoTimes, October 2026] [NoCamels, October 2024].
One source, partially checked -- Based primarily on company announcements, company website claims, and secondary coverage; no named direct startup competitors were confirmed in the provided public sources.
Opportunity
PUBLIC
The prize here is not simply another weight-management supplement, it is the chance to become a repeat-purchase consumer brand for the fast-growing population trying to maintain weight loss after GLP-1 use, with a science-origin story that is unusual for a DTC product [EconoTimes, October 2026] [Citybiz, October 2026] [PR Newswire, July 2024].
The headline opportunity is fairly specific. If Metabolize can show that NATLEAN helps people taper off GLP-1 therapies while managing appetite and weight maintenance, it could occupy a gap that current drug makers do not directly own, especially for consumers who want a non-prescription option after discontinuation [EconoTimes, October 2026] [Citybiz, October 2026] [metabolize.life]. What makes that outcome reachable, rather than purely aspirational, is the combination of a Stanford-originated license, a defined first product, a live consumer offer on the company website priced at $69 per month, and fresh seed capital earmarked for development, validation, manufacturing, and commercialization [PR Newswire, July 2024] [metabolize.life] [EconoTimes, October 2026]. That is still early evidence, and much of it is company-led, but it is enough to suggest a concrete go-to-market wedge rather than a broad metabolic-health ambition with no product attached [Citybiz, October 2026] [FinSMEs, October 2026].
The upside can be framed through a small set of distinct scale paths.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Post-GLP-1 default brand | NATLEAN becomes a recognized consumer product for people coming off GLP-1s and trying to maintain results without a prescription | January 2027 launch and successful early retention after first purchase [Citybiz, October 2026] [metabolize.life] | The company has centered the product around the GLP-1 transition use case in both financing coverage and its own consumer messaging, which gives it a sharper entry point than a general wellness supplement [EconoTimes, October 2026] [metabolize.life] |
| Stanford-to-shelf platform | The first product works well enough commercially that Metabolize extends the licensed metabolite approach into a broader portfolio across appetite, glucose, or muscle-support adjacencies | Commercial launch plus follow-on formulation pipeline from the Stanford-licensed metabolite base [PR Newswire, July 2024] [NoCamels, October 2024] | Public reporting says the company licensed two proprietary metabolites from Stanford for nutraceutical development, which implies optionality beyond a single SKU if efficacy and consumer demand hold [PR Newswire, July 2024] [NoCamels, October 2024] |
| Science-backed metabolic membership | The company converts a supplement sale into an ongoing DTC subscription relationship around long-run metabolic maintenance | Existing $69 per month website offer and a consumer condition that often requires ongoing support [metabolize.life] | The website already presents NATLEAN as a monthly offering, and weight maintenance is usually a repeat-use category rather than a one-time purchase, which can support recurring revenue if churn is manageable [metabolize.life] |
These scenarios share the same underlying compounding logic. One successful product launch could create three reinforcing assets: branded trust in a category where many products look interchangeable, repeat-purchase behavior through a monthly supplement model, and a larger body of consumer outcome data that could improve messaging, targeting, and future product design [metabolize.life] [EconoTimes, October 2026]. The flywheel is not a network effect in the software sense. It is closer to a consumer-health loop in which credible science supports conversion, conversion supports retention learning, and retention supports the capital and distribution needed to broaden the product line. The early signs are modest but real: the company has an exclusive Stanford license, participation from named seed investors, and an IndieBio cohort affiliation that can help with scientific and commercialization visibility at a stage when third-party validation matters [PR Newswire, July 2024] [EconoTimes, October 2026] [IndieBio / LinkedIn, January 2026].
The size of the win depends on whether Metabolize remains a single-product supplement seller or becomes a broader metabolic-health platform. A useful public comparable for the category's commercial ceiling is not a direct company match but the scale of the problem area itself. Reporting around Metabolize consistently anchors the company to obesity and GLP-1 step-down support, two categories that have drawn sustained investor and consumer attention because drug-led weight loss creates a follow-on maintenance question rather than a one-time event [NoCamels, October 2024] [EconoTimes, October 2026]. If the company were to establish a durable subscription base around that maintenance layer, then a meaningful outcome could resemble a high-quality consumer health asset with recurring revenue and line-extension potential. Any valuation translation here is necessarily a scenario, not a forecast: if Metabolize proves strong retention on a monthly product and expands into a metabolite-based portfolio under its Stanford license, the company could plausibly support venture-scale value creation as a branded metabolic-health platform rather than as a single supplement SKU (scenario, not a forecast) [PR Newswire, July 2024] [Citybiz, October 2026] [metabolize.life]. Public evidence does not yet support a tighter valuation range.
No independent source found -- This section relies heavily on company statements and company-derived coverage, with partial corroboration from multiple public reports including PR Newswire, EconoTimes, Citybiz, FinSMEs, NoCamels, the company website, and IndieBio / LinkedIn.
Sources
Publicly reported
[EconoTimes, October 2026] Metabolize Says It Raised $3.2 Million to Advance Metabolic-Health Products | https://econotimes.com/Metabolize-Says-It-Raised-3-2-Million-to-Advance-Metabolic-Health-Products-1755078
[PR Newswire, July 2024] Metabolize Licenses Two Proprietary Metabolites to Address Obesity from Stanford OTL | https://www.prnewswire.com/news-releases/metabolize-licenses-two-proprietary-metabolites-to-address-obesity-from-stanford-otl-302210129.html
[FinSMEs, October 2026] Metabolize Raises $3.2M in Seed Funding | https://www.finsmes.com/2026/10/metabolize-raises-3-2m-in-seed-funding.html
[metabolize.life] Metabolize | https://metabolize.life/
[LinkedIn, Retrieved 2026] Gideon Meir - Metabolize | https://www.linkedin.com/in/gideon-meir-4a5910128/
[Citybiz, October 2026] Metabolize Raises $3.2M Seed Round to Commercialize Stanford-Backed Metabolic Health Technology | https://www.citybiz.co/article/919035/metabolize-raises-3-2m-seed-round-to-commercialize-stanford-backed-metabolic-health-technology/
[NoCamels, October 2024] Harnessing Our Own Bodies For Side-Effect-Free Weight Loss | https://nocamels.com/2024/09/harnessing-our-own-bodies-for-side-effect-free-weight-loss/
[Bloomberg, Retrieved 2026] Morris Laster, OurCrowd Ltd: Profile and Biography | https://www.bloomberg.com/profile/person/1796177
[TechCrunch, September 2022] OurCrowd announces its new $200M Global Health Equity fund | https://techcrunch.com/2022/09/19/ourcrowd-announces-its-new-200m-global-health-equity-fund/
[IndieBio / LinkedIn, January 2026] IndieBio SF Batch 25H2 Demo Day | https://www.linkedin.com/posts/camillewatson_metabolize-indiebio-sf-batch-25h2-demo-activity-7423079132625838080-PD4l
Articles about Metabolize
- Metabolize Raises $3.2 Million to Build a Bridge From Weight-Loss Drugs — The startup's NATLEAN supplement, licensed from Stanford Medicine, is a bet on the metabolic challenges that follow blockbuster weight-loss therapies.